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Abstract: Attention-deficit/hyperactivity disorder (ADHD) is a behavioral disorder characterized 
by atypical levels of inattention, hyperactivity, and impulsivity that impair daily living activities. 
Although commonly associated with children and adolescents, current literature and practice 
now demonstrate the impairment the disorder may impose on adults as well. Central nervous 
system (CNS) stimulant medications are the first-line therapy for ADHD. CNS stimulants 
include methylphenidate and amphetamine derivatives. Longer-acting formulations used once 
daily are often preferred to avoid medication administration during school or work as well as 
to avoid side effects associated with rapid fluctuations in serum concentrations associated with 
multiple daily dosing. Lisdexamfetamine, a new, novel amphetamine product, has been shown 
to provide efficacy upwards of 12 hours in children and adults with a side effect profile similar 
to those of other longer-acting amphetamine products. Owing to its unique prodrug composition 
and the need for oral administration to activate the medication, lisdexamfetamine may offer 
advantages in clinical situations where stimulant abuse is a concern.
Keywords: lisdexamfetamine, Vyvanse, ADHD, attention-deficit/hyperactivity disorder, 
stimulants
Introduction
Attention-deficit/hyperactivity disorder (ADHD), a behavioral disorder characterized 
by impairments in daily living activities by atypical levels of inattention, hyperactivity, 
and/or impulsivity, affects as many as 7% of American children and 5% of adults.1,2 
Worldwide, approximately 5% of children have been diagnosed with ADHD.3 Central 
nervous system (CNS) stimulants are recommended as first-line medication therapy 
for children4 and have demonstrated efficacy in treating adults with ADHD as well.5,6 
CNS stimulants include formulations of methylphenidate (MPH) and amphetamine-
derivatives, and are available in a large variety of immediate- and extended-release 
preparations. Extended-release preparations are often preferred to limit drug admin-
istration during school or work and may help to limit side effects associated with 
rapid fluctuations in serum concentration. Lisdexamfetamine (Vyvanse®; Shire 
Pharmaceuticals, Wayne, PA, USA), a prodrug of dextroamphetamine, is approved 
in the US for the treatment of ADHD in children aged 6 to 12 years and adults aged 
18 to 55 years.7 The unique pharmacokinetics of the medication resulting from its 
prodrug design allow for a longer duration of activity and may also help to limit 
abuse of the agent.Therapeutics and Clinical Risk Management 2009:5 944
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The characteristics of ADHD across the age spectrum 
are becoming better understood. Individual symptoms of 
hyperactivity and inattention, for example, are not necessar-
ily constant, and may decrease with age.8,9 That is not to say, 
however, that children will outgrow a diagnosis of ADHD. 
According to one review, nearly 75% of children diag-
nosed with ADHD continue to meet diagnostic criteria into 
adolescence or young adulthood.10 Changes in symptomatic 
behaviors, and the impairment they may present, necessitate 
continuous review of medication treatment including adjust-
ment or discontinuation when warranted.
Doses of immediate-release formulations of MPH, 
dextroamphetamine, and mixed-amphetamine salts (MAS) 
are often administered twice daily: once in the morning and 
again at lunchtime or early afternoon. Extended-release 
medications have shown better levels of adherence and 
improved clinical outcomes in both children and adults.11,12 
Extended-release formulations administered in the morning 
help to simplify the adult’s medication dosing schedule. 
Extended-release formulations also eliminate the need for 
separate prescriptions, medication supply, and reliance on 
the school nurse for the schoolchild, not to mention potential 
social stigmatism. Though not a pharmaceutically designed 
extended-release formulation, once-daily administration of 
lisdexamfetamine (LDX) does provide efficacy throughout 
the day for both children and adults.13,14 The duration of 
LDX’s clinical effect is comparable to that of osmotically-
released MPH and extended-release MAS.
Abuse, misuse, and diversion of stimulant medications 
may also complicate the treatment of ADHD. Abuse is often 
considered to describe intentionally using large doses of a 
medication to achieve a desired effect, eg, euphoria, seda-
tion, hallucinations. Conversely, misuse describes the use of 
a prescription medication often without a prescription for 
its intended use. Inconsistencies in terminology can lead to 
difficulty interpreting abuse and misuse data of stimulant 
medications. In one sample of 4580 US college students, 
nearly 2% of those who had never received a prescription for 
CNS stimulants reported using one illicitly in the past 30 days. 
This increased to 8% for those who began prescription-
stimulant use during high school and to nearly 23% in those 
who began treatment during college. For those reporting 
illicit use of a stimulant medication, the odds of having begun 
legitimate treatment with a prescription stimulant during high 
school was 3.7; the odds of having begun legitimate treatment 
during college was 13.15 One review of misuse and diversion 
described the rate of high school and college students who 
sold, traded, or gave away their stimulant medications as 
high as 16% to 29%.16 Setlik et al described a 76% increase 
in poison control center calls related to adolescents abusing 
stimulant medications over the period of 1998 to 2005.17 
This was contrasted with a 55% increase in all calls related 
to adolescents over the same 8-year period. The authors 
also compared the increase in stimulant-related calls to the 
increase in stimulant medication prescriptions that increased 
by 86% over the same time frame. Owing once again to its 
unique prodrug nature and metabolism, LDX may pose a 
safer alternative for those concerned with abuse or diversion 
of stimulant medications.
This review will examine the mechanism of action and 
unique pharmacology and pharmacokinetics of LDX, discuss 
the safety and efficacy published to date in children and 
adults, and describe the potential place in therapy LDX may 
hold in the treatment of ADHD.
Pharmacology and pharmacokinetics
LDX is a prodrug of dextroamphetamine. It consists of 
an l-lysine moiety covalently bound to the active parent 
compound. As such, the mechanism of action of LDX is 
essentially the same as other amphetamine-derivatives. 
Within the CNS, these noncatecholamine sympathomimetic 
agents increase the synaptic activity of dopamine and nor-
epinephrine. This is accomplished by increasing the release 
of the neurotransmitter into the synaptic cleft, decreasing 
reuptake back into the presynaptic neuron, and inhibiting 
their catabolism.18 Potentiating the activity of dopamine 
and norepinephrine within certain brain structures, eg, the 
prefrontal cortex, may help to regulate motor and behavioral 
responses to external stimuli.
The rate-limited metabolism of LDX and subsequent 
release of the active parent compound dextroamphet-
amine is the characteristic that sets LDX apart from other 
amphetamine-derivatives. Following oral administration, 
the l-lysine moiety is cleaved from the parent dextroam-
phetamine compound via enzymatic biotransformation in 
the intestine and liver.7 In pharmacokinetic studies of both 
children and adults, this has resulted in higher maximum 
serum concentrations (Cmax) of dextroamphetamine as well as 
greater area-under-the-curve (AUC) profiles when compared 
to a similar dose of extended-release MAS. In a phase II trial 
of 52 children aged 6 to 12 years, Biederman et al described 
the Cmax of dextroamphetamine administered as 70 mg of 
LDX as 155 ng/mL and a 12-hour AUC of 1326 ng⋅h/mL 
compared to 119 ng/mL and 1019 ng⋅h/mL when adminis-
tered as 30 mg extended-release MAS.19 In adults, the Cmax 
following administration of LDX 70 mg was determined Therapeutics and Clinical Risk Management 2009:5 945
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to be 80.3 to 90.1 ng/mL20,21 and 24-hour AUC was 
1113 ng⋅h/mL.21 Food may slow the time to maximum serum 
concentrations by 1 hour.22 These pharmacokinetic charac-
teristics are what allow LDX to be utilized as a once-daily 
medication. Following biotransformation, dextroamphet-
amine is hepatically metabolized to inactive compounds or 
renally eliminated unchanged.
Clinical trials
LDX was originally studied in and subsequently approved by 
the US Food and Drug Administration (FDA) for the treat-
ment of ADHD in children aged 6 to 12 years. In the same 
phase II study mentioned previously, the efficacy of LDX 
compared to extended-release MAS was determined.19 In a 
blinded, placebo-controlled, crossover manner, Biederman 
et al compared the effects on classroom ADHD symptoms 
of a subject-specific effective dose of extended-release MAS 
to an equivalent dose of LDX. Both extended-release MAS 
and LDX significantly improved ADHD symptoms compared 
to baseline assessments. Assessments of symptoms were 
made frequently on the last day of treatment to determine 
the effects of treatment over time. At 2 hours, both extended-
release MAS and LDX showed significant improvements 
compared to placebo. This effect peaked at 6 hours before 
trending back towards the day’s baseline value within 10 to 
12 hours. A clinically meaningful difference between LDX 
and extended-release MAS was not demonstrated.
Biederman et al used a placebo-controlled, forced-
dose escalation design in their phase III study involving 
290 children aged 6 to 12 years.14 Patients were randomized 
and titrated to a final dose of 30, 50, or 70 mg LDX/day or 
placebo over a course of 3 weeks. A clinician-rated ADHD 
symptom-assessment tool was used to assess the changes 
in symptom severity from baseline to endpoint at 4 weeks. 
All three doses of LDX significantly improved symptom 
scores by the end of the study; the improvement was seen 
as soon as one week of treatment when all active groups 
received 30 mg/day. Between-dose comparisons showed 
a small albeit statistically significant advantage of the 
70 mg/day dose compared to 30 mg/day.
A post-hoc analysis of data collected in the phase III 
trial demonstrated significant improvements in parent-rated 
ADHD symptom scores measured at 10 AM, 2 PM, and 
6 PM during the weekly assessment days in the children 
receiving LDX compared to those receiving placebo.23 This 
analysis further showed significant improvements throughout 
the day in parent-rated scores of specific behaviors such as 
hyperactivity and opposition. The continued reductions in 
parent-rated symptom scores at 6 PM, approximately 10 hours 
after administration, reinforce the pharmacokinetically 
derived extended duration of LDX.
Wigal et al performed a laboratory-classroom study 
similar to the phase II trial discussed above.24 The purpose 
of this study was to further describe the onset and duration of 
LDX effect during the school day. After a 4-week, open-label, 
dose-optimization period, 117 subjects were randomized into 
the placebo-controlled crossover phase of the study. Subjects 
received their randomized medication (best-dose LDX or 
placebo) daily for 1 week, the end of which culminated in a 
laboratory classroom session. During this laboratory class-
room assessments of ADHD behavior were made by clini-
cal observers 0.5 hour before administration and again 1.5, 
2.5, 5, 7.5, 10, 12, and 13 hours post dose. Although LDX 
demonstrated significantly better improvements in ADHD 
behavior compared to placebo at all post-dose time points, 
the assessments made at 12 and 13 hours post dose were not 
significantly improved compared to the pre-dose assessment. 
Compared to the pre-dose assessment, LDX demonstrated 
significant improvement through 10 hours, again reflecting 
the long-acting nature of the drug.
Findling et al have been the only to date to examine the 
long-term benefits of LDX in children aged 6 to 12 years.25 
After titrating subjects to an effective dose over 4 weeks, 
subjects continued open-label LDX treatment for an addi-
tional 11 months. Clinician-rated ADHD symptom scores 
decreased significantly from baseline within 1 week of 
beginning treatment and reached maximum benefit by the 
fourth week. Scores describing inattention symptoms and 
hyperactivity symptoms decreased by approximately 60% 
and 66%, respectively. These improvements were maintained 
throughout the remaining 11-month study period.
In a study similar in design to Biederman et al’s phase III 
study in children, Adler et al established the efficacy of LDX 
in treating adults aged 18 to 55 years with ADHD.13 Follow-
ing randomization to placebo, LDX 30 mg/day, 50 mg/day, 
or 70 mg/day, 414 adults were assessed for improvements 
in clinician-rated ADHD symptoms. All doses of LDX 
demonstrated significantly better improvements in ADHD 
symptom scores compared to placebo. As well, a significantly 
greater number of subjects receiving LDX showed at least 
30% improvement from baseline in clinician-rated ADHD 
scores compared to placebo.
Safety and tolerability
Side effects reported in studies of both children and adults 
were similar in incidence to those of other CNS stimulants. Therapeutics and Clinical Risk Management 2009:5 946
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Notable adverse effects that were reported more often in 
those receiving LDX treatment compared to placebo included 
decreased appetite, insomnia, irritability, weight decrease, 
headache, and upper abdominal pain.13,14,24 The reported 
incidences of these are listed in Table 1. The nature of the 
reported adverse effects and their incidence were generally 
similar in phase III trials of both children and adults. Out of 
a total of 28 reports to poison control centers in 8 states, side 
effects with greater than a 10% incidence included: agita-
tion (43%), tachycardia (39%), insomnia (29%), dystonia 
(29%), vomiting (18%), chest pain (14%), hallucinations 
(11%) and jitters (11%).26 These adverse effects tend to be 
most prevalent during the initiation of treatment with LDX, 
or following an increase in dose. Although they tended to be 
transient in nature, side effects of LDX led to discontinua-
tion of 6%–9% of subjects in the phase III trials of children 
and adults.13,14
Sleep difficulties and insomnia are some of the most 
frequently reported side effects of LDX. Wigal et al reported 
an incidence of insomnia of 27% among children treated with 
LDX.24 A post-hoc analysis of the phase III trial in adults 
provides more information however regarding the nature 
of sleep in adults diagnosed with ADHD and the effects of 
LDX.27 At baseline, subjects randomized to placebo and LDX 
were both found to have poor sleep quality as demonstrated 
by a validated self-reported sleep quality questionnaire. This 
confirms other data describing the sleep habits of individuals 
with ADHD, regardless of stimulant treatment. Although 
19% of the adults randomized to receive LDX reported 
insomnia compared to approximately 5% of those random-
ized to placebo, the changes from baseline in the self-reported 
sleep quality questionnaire were not significantly different 
between the two.
Minimal increases in pulse and blood pressure are often 
reported with CNS stimulants. Similar findings were reported 
in the studies of LDX in children. Wigal et al reported a 
maximum increase in pulse of approximately 7 beats per 
minute (bpm) for all doses of LDX at 12.5 hours after 
administration; the increase in pulse reported in the 70 mg 
group was approximately 10 bpm.24 Similarly, those same 
authors reported increases in systolic (SPB) and diastolic 
(DBP) blood pressures of approximately 4 and 5 mmHg, 
respectively, 8 hours after administration of a 70 mg LDX 
dose. Compared to placebo, Biederman et al’s phase II trial 
reported statistically significant increases in DBP of 4.6 to 
4.8 mmHg and in pulse of 6.7 bpm, at 2.5 to 5 hours fol-
lowing administration. There were no differences when 
compared to comparable doses of extended-release MAS.19 
Findling’s long-term open-label study reported an increase in 
pulse 2 bpm, and 1 mmHg for both SPB and DBP follow-
ing 12 months of treatment.25 In adults, Adler et al reported 
significant increases in pulse of approximately 3 to 5 bpm.13
Despite some findings of statistically significant 
changes in electrocardiogram measurements, no clinically 
significant cardiac conduction changes were described in 
the phase II and III trials as well as Findling’s long-term 
extension trial.13,14,19,25 However, like other amphetamine 
products, labeling for LDX does include a black box warning 
describing sudden death associated with misuse of the agent. 
In addition, although not specifically reported in use of LDX, 
there are case reports of sudden death associated with the 
therapeutic use of CNS stimulants. Although a definitive risk 
relationship between the therapeutic use of CNS stimulants 
and sudden death has yet to be determined, the American 
Academy of Pediatrics and the American Heart Association 
both recommend a thorough family and medical history and 
physical examination prior to beginning therapy to identify 
risk factors for sudden cardiac death.28,29 The American 
Heart Association also recommends baseline electrocardio-
gram tests.28
The long-term effects that stimulant therapy has on 
growth are still debated. At the end of Findling et al’s 
12-month extension study, the age- and sex-normalized 
z-score for height was –0.08; this was statistically signifi-
cant when compared to baseline.25 The normalized z-score 
for weight was –0.4, but this was not statistically significant 
compared to baseline. More data from prolonged use of LDX 
is necessary to fully understand the effects the agent will have 
on growth of children.
The unique prodrug design of LDX may also help to 
limit the abuse potential of the agent. The biotransformation 
of LDX to active dextroamphetamine occurs following oral 
administration in the intestine and liver.7 Bypassing oral 
administration, which may occur in cases of abuse or misuse 
when the formulation is crushed and snorted intranasally or 
Table 1 Adverse effects of lisdexamfetamine
Adverse effect  Incidence reported in 
clinical efficacy trials13,14,24
Decreased appetite 22%–47%
insomnia 14%–27%
Headache 12%–17%
Upper abdominal pain 12%–16%
irritability 10%–16%
weight decrease 9%Therapeutics and Clinical Risk Management 2009:5 947
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dissolved for intravenous injection, greatly diminishes the 
subsequent serum concentrations of dextroamphetamine. 
Jasinski et al demonstrated this by administering comparable 
doses of LDX and dextroamphetamine intravenously to adult 
stimulant abusers.30 The maximum dextroamphetamine 
serum concentration resulting from LDX administration 
was 20.7 ng/mL compared to a serum concentration of 
74.2 ng/mL when administered as the active dextroamphet-
amine. The subjects also scored the effects of LDX admin-
istered intravenously lower than dextroamphetamine on a 
validated drug-likability scale. In a study of orally adminis-
tered LDX, adult substance abusers reported a statistically 
greater preference for control doses of dextroamphetamine 
and diethylpropion compared to LDX doses  100 mg; the 
preference for LDX 150 mg was statistically no different 
than that of the controls.31 Lisdexamfetamine is classified 
as a schedule-II narcotic by the US Drug Enforcement 
Agency.32
Patient considerations
The benefits of LDX for the treatment of ADHD in children 
and adults include clinical improvement comparable to that 
of extended-release MAS and once-daily administration. 
For young children unable to swallow tablets, the capsule 
of LDX may be opened and the contents dissolved in a 
glass of water for administration.7 This unique advantage 
allows for a long-acting formulation that does not need to be 
swallowed whole. The formulations of the primary compara-
tors of LDX, extended-release MAS and osmotically-released 
MPH, do not allow for this point-of-care extemporaneous 
solution. Food may slow the time needed to achieve the 
maximum serum concentration for the dose by approximately 
one hour.22 Similar to other long-acting CNS stimulants, 
LDX may be administered only on school or workdays 
if preferred. Longer drug holidays are possible too if the 
patient chooses. Although no cost-benefit analysis of LDX 
has yet been performed, the average wholesale price of 
Vyvanse® (LDX, Shire Pharmaceuticals, Wayne, PA, USA) 
is less than that of Adderall XR® (extended-release MAS, 
Shire Pharmaceuticals, Wayne, PA, USA) and Teva USA’s 
generically available extended-release MAS formulation: 
$4.89/Vyvanse® capsule vs $7.49/Adderall XR® capsule vs 
$6.13/generic extended-release MAS capsule.33
A significant disadvantage currently is the lack of data 
demonstrating efficacy and safety of LDX in adolescents aged 
13 to 17 years. Clinical trials of LDX within this population 
are ongoing however. LDX also has not distanced itself from 
other long-acting CNS stimulants in terms of efficacy and 
side effects. Future prospective, head-to-head comparisons 
may help to describe the place in therapy of LDX relative to 
its primary comparators, extended-release MAS and osmoti-
cally released MPH.
Summary and conclusions
LDX is the latest CNS stimulant to be approved by the FDA 
for the treatment of ADHD. Its unique pharmacokinetic pro-
file and long duration of activity result from the rate-limited 
biotransformation of the prodrug compound to the active 
agent, dextroamphetamine. As such, the mechanism of action, 
efficacy, and side effect profile of LDX are similar to those of 
other amphetamine derivatives. LDX has been demonstrated 
to attenuate symptoms of ADHD in children and adults for 
as long as 10 hours. Common side effects include decreased 
appetite, insomnia, headache, and irritability.
In conclusion, LDX does offer another effective and 
long-acting option for the treatment of ADHD in both 
children and adults and can be considered an appropriate 
choice for first-line treatment of those populations. LDX 
may be a preferred agent in clinical situations where there 
is a concern by the patient, parent, or clinician of abuse or 
diversion, or in individuals unable to swallow an extended-
release formulation.
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